Labcorp Holdings Inc (LH)

NYSE
Currency in USD
217.12
-3.45(-1.56%)
Closed·
After Hours
217.120.00(0.00%)
·
LH Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 9 days
Fair Value
Day's Range
216.92220.41
52 wk Range
191.97258.59
Key Statistics
Edit
Prev. Close
220.57
Open
219.25
Day's Range
216.92-220.41
52 wk Range
191.97-258.59
Volume
762.21K
Average Volume (3m)
710.04K
1-Year Change
7.76%
Book Value / Share
96.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
270.51
Upside
+24.59%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period
Show more

Labcorp Holdings Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

Labcorp Holdings Inc SWOT Analysis


Financial Resilience
Labcorp demonstrates robust financial performance with strong Q2 earnings, leading to raised revenue growth guidance and positive market response
Leadership Transition
Explore the potential impact of new CFO Julia Wang, whose diverse experience in diagnostics and biotech could drive strategic financial decisions
Market Positioning
Delve into Labcorp's competitive stance in the dynamic life sciences industry, where innovation and strategic moves shape future prospects
Growth Projections
Analysts project steady EPS growth, with estimates reaching 15.54 for FY 2026, while Barclays Capital sets a price target of $249.00
Read full SWOT analysis

Labcorp Holdings Inc Earnings Call Summary for Q3/2024

  • Q3 revenue up 7% YoY to $3.3B; adjusted EPS grew 4% to $3.50; diagnostics revenue +9%, biopharma services +3%
  • Completed acquisitions, launched new products; adjusted operating income $441M; margin decline due to Invitae acquisition
  • Projecting 6.6-7.3% enterprise revenue growth for 2024; adjusted EPS guidance $14.30-$14.70; free cash flow $850M-$980M
  • Diagnostics Labs revenue +8.9% to $2.6B; Biopharma Labs +2.6% to $738M; $8.1B backlog; long-term biopharma growth ~6%
  • Expects $100M-$125M savings from LaunchPad; capital expenditures ~3.5% of revenue; margin improvements in H2 2025
Last Updated: 24/10/2024, 23:02
Read Full Transcript

Compare LH to Peers and Sector

Metrics to compare
LH
Peers
Sector
Relationship
P/E Ratio
24.4x22.3x−0.5x
PEG Ratio
0.290.260.00
Price/Book
2.3x1.3x2.6x
Price / LTM Sales
1.4x1.8x2.9x
Upside (Analyst Target)
24.4%24.5%66.3%
Fair Value Upside
Unlock−6.0%10.2%Unlock

Analyst Ratings

17 Buy
3 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 270.51
(+24.59% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.89%
Dividend Yield
1.33%
Industry Median 1.57%
Annualised payout
2.88
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 06, 2025
EPS / Forecast
3.45 / 3.39
Revenue / Forecast
3.33B / 3.31B
EPS Revisions
Last 90 days

People Also Watch

97.92
ZBH
+1.01%
64.73
HSIC
+2.28%
34.15
FITB
-0.73%
205.76
CTAS
+0.51%
260.22
CDNS
+0.37%

FAQ

What Is the Labcorp Holdings (LH) Stock Price Today?

The Labcorp Holdings stock price today is 217.12

What Stock Exchange Does Labcorp Holdings Trade On?

Labcorp Holdings is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Labcorp Holdings?

The stock symbol for Labcorp Holdings is "LH."

Does Labcorp Holdings Pay Dividends? What’s The Current Dividend Yield?

The Labcorp Holdings dividend yield is 1.33%.

What Is the Labcorp Holdings Market Cap?

As of today, Labcorp Holdings market cap is 18.17B.

What is Labcorp Holdings Earnings Per Share?

The Labcorp Holdings EPS is 8.89.

What Is the Next Labcorp Holdings Earnings Date?

Labcorp Holdings will release its next earnings report on 28 Apr 2025.

From a Technical Analysis Perspective, Is LH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.